While clinical trials for anti-inflammatory therapies in heart failure such as the use of TNFα antagonists yielded mixed results (reviewed in refs. 34,35), there is renewed interest in such an approach as e.g. a sub-analysis of the CANTOS trial revealed that interleukin 1β-blockade improved ejection fraction and heart failure symptoms36. The gene discussed is TNF; the disease is heart failure.